Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection

Anaerobe

Volumn 41, Issue , 2016, Pages 37-43

  Ross, Caná L ^a,b   Spinler, Jennifer K ^a,b   Savidge, Tor C ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

CDI; Clostridium difficile; Metabolome; Microbiome

Indexed keywords

AMINO ACID;

ARTICLE; BILE ACID METABOLISM; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY STRUCTURE; DISEASE ASSOCIATION; DYSBIOSIS; FERMENTATION; HUMAN; INFECTION SENSITIVITY; INTESTINE FLORA; METABOLITE; METABOLOME; METABOLOMICS; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PHENOTYPE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ANIMAL; DISEASE PREDISPOSITION; GASTROINTESTINAL TRACT; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; PSEUDOMEMBRANOUS COLITIS;

ANIMALS; CLOSTRIDIUM DIFFICILE; DISEASE SUSCEPTIBILITY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HOST-PATHOGEN INTERACTIONS; HUMANS; METABOLOME;

EID: 84969581211     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2016.05.006     Document Type: Article

References (145)

1. [1] Magill, S.S., et al. Multistate point-prevalence survey of health care-associated infections. N. Engl. J. Med. 370 (2014), 1198–1208.
2. [2] Kelly, C.P., LaMont, J.T., Clostridium difficile–more difficult than ever. N. Engl. J. Med. 359 (2008), 1932–1940.
3. [3] Lessa, F.C., Winston, L.G., McDonald, L.C., E. I. P. C. d. S. Team. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372 (2015), 2369–2370.
4. [4] Kelly, C.P., LaMont, J.T., Clostridium difficile infection. Annu. Rev. Med. 49 (1998), 375–390.
5. [5] Voth, D.E., Ballard, J.D., Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18 (2005), 247–263.
6. [6] Just, I., et al. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375 (1995), 500–503.
7. [7] Just, I., et al. The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J. Biol. Chem. 270 (1995), 13932–13936.
8. [8] Madan, R., Petri, W.A. Jr., Immune responses to Clostridium difficile infection. Trends Mol. Med. 18 (2012), 658–666.
9. [9] Kyne, L., Warny, M., Qamar, A., Kelly, C.P., Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342 (2000), 390–397.
10. [10] Kelly, C.P., Kyne, L., The host immune response to Clostridium difficile. J. Med. Microbiol. 60 (2011), 1070–1079.
11. [11] Wullt, M., Norén, T., Ljungh, A., Åkerlund, T., IgG antibody response to toxins A and B in patients with Clostridium difficile infection. Clin. Vaccine Immunol. 19 (2012), 1552–1554.
12. [12] Leav, B.A., et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28 (2010), 965–969.
13. [13] Henrich, T.J., Krakower, D., Bitton, A., Yokoe, D.S., Clinical risk factors for severe Clostridium difficile-associated disease. Emerg. Infect. Dis. 15 (2009), 415–422.
14. [14] Dethlefsen, L., Huse, S., Sogin, M.L., Relman, D.A., The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol., 6, 2008, e280.
15. [15] Dethlefsen, L., Relman, D.A., Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl. Acad. Sci. U. S. A. 108:Suppl. 1 (2011), 4554–4561.
16. [16] Antunes, L.C., et al. Effect of antibiotic treatment on the intestinal metabolome. Antimicrob. Agents Chemother. 55 (2011), 1494–1503.
17. [17] Salazar, N., et al. Microbial targets for the development of functional foods accordingly with nutritional and immune parameters altered in the elderly. J. Am. Coll. Nutr. 32 (2013), 399–406.
18. [18] Lawley, T.D., Walker, A.W., Intestinal colonization resistance. Immunology 138 (2013), 1–11.
19. [19] Britton, R.A., Young, V.B., Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol. 20 (2012), 313–319.
20. [20] Caballero, S., Pamer, E.G., Microbiota-mediated inflammation and antimicrobial defense in the intestine. Annu. Rev. Immunol. 33 (2015), 227–256.
21. [21] Salzman, N.H., Paneth cell defensins and the regulation of the microbiome: détente at mucosal surfaces. Gut Microbes 1 (2010), 401–406.
22. [22] Ng, K.M., et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 502 (2013), 96–99.
23. [23] Maltby, R., Leatham-Jensen, M.P., Gibson, T., Cohen, P.S., Conway, T., Nutritional basis for colonization resistance by human commensal Escherichia coli strains HS and Nissle 1917 against E. coli O157:H7 in the mouse intestine. PLoS One, 8, 2013, e53957.
24. [24] Wilson, K.H., Perini, F., Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect. Immun. 56 (1988), 2610–2614.
25. [25] Sambol, S.P., Merrigan, M.M., Tang, J.K., Johnson, S., Gerding, D.N., Colonization for the prevention of Clostridium difficile disease in hamsters. J. Infect. Dis. 186 (2002), 1781–1789.
26. [26] Giel, J.L., Sorg, J.A., Sonenshein, A.L., Zhu, J., Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One, 5, 2010, e8740.
27. [27] Ridlon, J.M., Kang, D.J., Hylemon, P.B., Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47 (2006), 241–259.
28. [28] Theriot, C.M., Bowman, A.A., Young, V.B., Antibiotic-induced alterations of the gut microbiota alter secondary bile acid production and allow for Clostridium difficile spore germination and outgrowth in the large intestine. mSphere, 1, 2016 e00045-15.
29. [29] Theriot, C.M., et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat. Commun., 5, 2014, 3114.
30. [30] Jump, R.L., et al. Metabolomics analysis identifies intestinal microbiota-derived biomarkers of colonization resistance in clindamycin-treated mice. PLoS One, 9, 2014, e101267.
31. [31] Hasegawa, M., et al. Protective role of commensals against Clostridium difficile infection via an IL-1β-mediated positive-feedback loop. J. Immunol. 189 (2012), 3085–3091.
32. [32] Brandl, K., et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature 455 (2008), 804–807.
33. [33] Atarashi, K., et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331 (2011), 337–341.
34. [34] Umesaki, Y., Setoyama, H., Matsumoto, S., Imaoka, A., Itoh, K., Differential roles of segmented filamentous bacteria and clostridia in development of the intestinal immune system. Infect. Immun. 67 (1999), 3504–3511.
35. [35] Bibbò, S., et al. Role of microbiota and innate immunity in recurrent Clostridium difficile infection. J. Immunol. Res., 2014, 2014, 462740.
36. [36] Koo, H.L., et al. Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect. Control Hosp. Epidemiol. 35 (2014), 667–673.
37. [37] Planche, T.D., et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect. Dis. 13 (2013), 936–945.
38. [38] Murad, Y.M., et al. Impact of polymerase chain reaction testing on Clostridium difficile infection rates in an acute health care facility. Am. J. Infect. Control 43 (2015), 383–386.
39. [39] Dubberke, E.R., Burnham, C.A., Diagnosis of Clostridium difficile infection: treat the patient, not the test. JAMA Intern Med. 175 (2015), 1801–1802.
40. [40] Polage, C.R., et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med. 175 (2015), 1792–1801.
41. 41 Jackson, M., Olefson, S., Machan, J.T., Kelly, C.R., A high rate of alternative diagnoses in patients referred for presumed Clostridium difficile infection. J. Clin. Gastroenterol., 2015, 10.1097/MCG.0000000000000447.
42. [42] Whittier, S., et al. Evaluation of four commercially available enzyme immunoassays for laboratory diagnosis of Clostridium difficile-associated diseases. J. Clin. Microbiol. 31 (1993), 2861–2865.
43. [43] Gilligan, P.H., Optimizing the laboratory diagnosis of Clostridium difficile infection. Clin. Lab. Med. 35 (2015), 299–312.
44. [44] Fenner, L., Widmer, A.F., Goy, G., Rudin, S., Frei, R., Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J. Clin. Microbiol. 46 (2008), 328–330.
45. [45] McFarland, L.V., et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect. Control Hosp. Epidemiol. 20 (1999), 43–50.
46. [46] Kelly, C.P., Can we identify patients at high risk of recurrent Clostridium difficile infection?. Clin. Microbiol. Infect. 18:Suppl. 6 (2012), 21–27.
47. [47] Garey, K.W., Sethi, S., Yadav, Y., DuPont, H.L., Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J. Hosp. Infect. 70 (2008), 298–304.
48. [48] Garey, K.W., et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J. Antimicrob. Chemother. 66 (2011), 2850–2855.
49. [49] Ghantoji, S.S., Sail, K., Lairson, D.R., DuPont, H.L., Garey, K.W., Economic healthcare costs of Clostridium difficile infection: a systematic review. J. Hosp. Infect. 74 (2010), 309–318.
50. [50] Figueroa, I., et al. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin. Infect. Dis. 55:Suppl. 2 (2012), S104–S109.
51. [51] Cornely, O.A., et al. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J. Antimicrob. Chemother. 69 (2014), 2892–2900.
52. [52] Cornely, O.A., et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 12 (2012), 281–289.
53. [53] Cornely, O.A., Miller, M.A., Louie, T.J., Crook, D.W., Gorbach, S.L., Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin. Infect. Dis. 55:Suppl. 2 (2012), S154–S161.
54. [54] Youngster, I., et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin. Infect. Dis. 58 (2014), 1515–1522.
55. [55] Youngster, I., et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312 (2014), 1772–1778.
56. [56] Song, Y., et al. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One, 8, 2013, e81330.
57. [57] Dutta, S.K., et al. Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile Infection. Clin. Gastroenterol. Hepatol. 12 (2014), 1572–1576.
58. [58] Young, V.B., Schmidt, T.M., Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J. Clin. Microbiol. 42 (2004), 1203–1206.
59. [59] Walia, R., et al. Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome. J. Pediatr. Gastroenterol. Nutr. 59 (2014), 565–570.
60. [60] Walia, R., Kunde, S., Mahajan, L., Fecal microbiota transplantation in the treatment of refractory Clostridium difficile infection in children: an update. Curr. Opin. Pediatr. 26 (2014), 573–578.
61. [61] Shankar, V., et al. Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation. Microbiome, 2, 2014, 13.
62. [62] Gu, S., et al. Identification of key taxa that favor intestinal colonization of Clostridium difficile in an adult Chinese population. Microbes Infect. 18 (2016), 30–38.
63. [63] Antharam, V.C., et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J. Clin. Microbiol. 51 (2013), 2884–2892.
64. [64] Schubert, A.M., et al. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. MBio, 5, 2014 e01021–14.
65. [65] Vincent, C., et al. Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection. Microbiome, 1, 2013, 18.
66. [66] Zhang, L., et al. Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization. Anaerobe 34 (2015), 1–7.
67. [67] Buffie, C.G., et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517 (2015), 205–208.
68. [68] Rousseau, C., et al. Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. Clin. Infect. Dis. 55 (2012), 1209–1215.
69. [69] Rexach, C.E., Tang-Feldman, Y.J., Cantrell, M.C., Cohen, S.H., Epidemiologic surveillance of Clostridium difficile diarrhea in a freestanding pediatric hospital and a pediatric hospital at a university medical center. Diagn. Microbiol. Infect. Dis. 56 (2006), 109–114.
70. [70] Larson, H.E., Barclay, F.E., Honour, P., Hill, I.D., Epidemiology of Clostridium difficile in infants. J. Infect. Dis. 146 (1982), 727–733.
71. [71] Collignon, A., et al. Heterogeneity of Clostridium difficile isolates from infants. Eur. J. Pediatr. 152 (1993), 319–322.
72. [72] Yatsunenko, T., et al. Human gut microbiome viewed across age and geography. Nature 486 (2012), 222–227.
73. [73] Al-Jumaili, I.J., Shibley, M., Lishman, A.H., Record, C.O., Incidence and origin of Clostridium difficile in neonates. J. Clin. Microbiol. 19 (1984), 77–78.
74. [74] Koenig, J.E., et al. Succession of microbial consortia in the developing infant gut microbiome. Proc. Natl. Acad. Sci. U. S. A. 108:Suppl. 1 (2011), 4578–4585.
75. [75] Sjögren, Y.M., et al. Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses. Clin. Exp. Allergy 39 (2009), 1842–1851.
76. [76] Jauréguy, F., et al. Effects of intrapartum penicillin prophylaxis on intestinal bacterial colonization in infants. J. Clin. Microbiol. 42 (2004), 5184–5188.
77. [77] Penders, J., Stobberingh, E.E., van den Brandt, P.A., van Ree, R., Thijs, C., Toxigenic and non-toxigenic Clostridium difficile: determinants of intestinal colonisation and role in childhood atopic manifestations. Gut 57 (2008), 1025–1026.
78. [78] Eglow, R., et al. Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J. Clin. Investig. 90 (1992), 822–829.
79. [79] Ling, Z., et al. Impacts of infection with different toxigenic Clostridium difficile strains on faecal microbiota in children. Sci. Rep., 4, 2014, 7485.
80. [80] Chang, J.Y., et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 197 (2008), 435–438.
81. 81 Allegretti, J.R., et al. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment. Pharmacol Ther. 43 (2016), 1142–1153.
82. [82] Shahinas, D., et al. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing. MBio, 3, 2012.
83. [83] Weingarden, A.R., et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am. J. Physiol. Gastrointest. Liver Physiol. 306 (2014), G310–G319.
84. [84] Turnbaugh, P.J., et al. A core gut microbiome in obese and lean twins. Nature 457 (2009), 480–484.
85. [85] Rojo, D., et al. Clostridium difficile heterogeneously impacts intestinal community architecture but drives stable metabolome responses. ISME J. 9 (2015), 2206–2220.
86. [86] Sorg, J.A., Sonenshein, A.L., Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J. Bacteriol. 192 (2010), 4983–4990.
87. [87] Sorg, J.A., Sonenshein, A.L., Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination. J. Bacteriol. 191 (2009), 1115–1117.
88. [88] Sorg, J.A., Sonenshein, A.L., Bile salts and glycine as cogerminants for Clostridium difficile spores. J. Bacteriol. 190 (2008), 2505–2512.
89. [89] Wilson, K.H., Kennedy, M.J., Fekety, F.R., Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J. Clin. Microbiol. 15 (1982), 443–446.
90. [90] Wilson, K.H., Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J. Clin. Microbiol. 18 (1983), 1017–1019.
91. [91] Howerton, A., Patra, M., Abel-Santos, E., A new strategy for the prevention of Clostridium difficile infection. J. Infect. Dis. 207 (2013), 1498–1504.
92. [92] Wheeldon, L.J., Worthington, T., Hilton, A.C., Elliott, T.S., Lambert, P.A., Physical and chemical factors influencing the germination of Clostridium difficile spores. J. Appl. Microbiol. 105 (2008), 2223–2230.
93. [93] Wheeldon, L.J., Worthington, T., Lambert, P.A., Histidine acts as a co-germinant with glycine and taurocholate for Clostridium difficile spores. J. Appl. Microbiol. 110 (2011), 987–994.
94. [94] Wikoff, W.R., et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 3698–3703.
95. [95] Chung, K.T., Anderson, G.M., Fulk, G.E., Formation of indoleacetic acid by intestinal anaerobes. J. Bacteriol. 124 (1975), 573–575.
96. [96] Swann, J.R., et al. Variation in antibiotic-induced microbial recolonization impacts on the host metabolic phenotypes of rats. J. Proteom. Res. 10 (2011), 3590–3603.
97. [97] Hove, H., Tvede, M., Mortensen, P.B., Antibiotic-associated diarrhoea, Clostridium difficile, and short-chain fatty acids. Scand. J. Gastroenterol. 31 (1996), 688–693.
98. [98] Høverstad, T., et al. Influence of oral intake of seven different antibiotics on faecal short-chain fatty acid excretion in healthy subjects. Scand. J. Gastroenterol. 21 (1986), 997–1003.
99. [99] Høverstad, T., Midtvedt, T., Short-chain fatty acids in germfree mice and rats. J. Nutr. 116 (1986), 1772–1776.
100. [100] Romick-Rosendale, L.E., et al. NMR-based metabonomics analysis of mouse urine and fecal extracts following oral treatment with the broad-spectrum antibiotic enrofloxacin (Baytril). Magn. Reson Chem. 47:Suppl. 1 (2009), S36–S46.
101. [101] May, T., Mackie, R.I., Fahey, G.C., Cremin, J.C., Garleb, K.A., Effect of fiber source on short-chain fatty acid production and on the growth and toxin production by Clostridium difficile. Scand. J. Gastroenterol. 29 (1994), 916–922.
102. [102] Rolfe, R.D., Role of volatile fatty acids in colonization resistance to Clostridium difficile. Infect. Immun. 45 (1984), 185–191.
103. [103] Cherrington, C.A., Hinton, M., Pearson, G.R., Chopra, I., Short-chain organic acids at ph 5.0 kill Escherichia coli and Salmonella spp. without causing membrane perturbation. J. Appl. Bacteriol. 70 (1991), 161–165.
104. [104] Duncan, S.H., Louis, P., Thomson, J.M., Flint, H.J., The role of pH in determining the species composition of the human colonic microbiota. Environ. Microbiol. 11 (2009), 2112–2122.
105. [105] Gupta, P., et al. Does alkaline colonic pH predispose to Clostridium difficile infection?. South Med. J. 109 (2016), 91–96.
106. [106] Cook, S.I., Sellin, J.H., Review article: short chain fatty acids in health and disease. Aliment. Pharmacol. Ther. 12 (1998), 499–507.
107. [107] Wong, J.M., de Souza, R., Kendall, C.W., Emam, A., Jenkins, D.J., Colonic health: fermentation and short chain fatty acids. J. Clin. Gastroenterol. 40 (2006), 235–243.
108. [108] Borriello, S.P., Barclay, F.E., An in-vitro model of colonisation resistance to Clostridium difficile infection. J. Med. Microbiol. 21 (1986), 299–309.
109. [109] Lawley, T.D., et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog., 8, 2012, e1002995.
110. [110] Reichardt, N., et al. Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. ISME J. 8 (2014), 1323–1335.
111. [111] Ferreyra, J.A., et al. Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance. Cell Host Microbe 16 (2014), 770–777.
112. [112] Sandora, T.J., et al. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr. Infect. Dis. J. 30 (2011), 580–584.
113. [113] Sammons, J.S., Toltzis, P., Zaoutis, T.E., Clostridium difficile Infection in children. JAMA Pediatr. 167 (2013), 567–573.
114. [114] Sammons, J.S., et al. Diagnosis and management of Clostridium difficile infection by pediatric infectious diseases physicians. J. Pediatr. Infect. Dis. Soc. 3 (2014), 43–48.
115. [115] Leibowitz, J., Soma, V.L., Rosen, L., Ginocchio, C.C., Rubin, L.G., Similar proportions of stool specimens from hospitalized children with and without diarrhea test positive for Clostridium difficile. Pediatr. Infect. Dis. J. 34 (2015), 261–266.
116. [116] Scupham, A.J., Jones, J.A., Wesley, I.V., Comparison of DNA extraction methods for analysis of turkey cecal microbiota. J. Appl. Microbiol. 102 (2007), 401–409.
117. [117] Salonen, A., et al. Comparative analysis of fecal DNA extraction methods with phylogenetic microarray: effective recovery of bacterial and archaeal DNA using mechanical cell lysis. J. Microbiol. Methods 81 (2010), 127–134.
118. [118] Wu, J.Y., et al. Effects of polymerase, template dilution and cycle number on PCR based 16 S rRNA diversity analysis using the deep sequencing method. BMC Microbiol., 10, 2010, 255.
119. [119] Pinto, A.J., Raskin, L., PCR biases distort bacterial and archaeal community structure in pyrosequencing datasets. PLoS One, 7, 2012, e43093.
120. [120] Tremblay, J., et al. Primer and platform effects on 16S rRNA tag sequencing. Front. Microbiol., 6, 2015, 771.
121. [121] Kim, M., Morrison, M., Yu, Z., Evaluation of different partial 16S rRNA gene sequence regions for phylogenetic analysis of microbiomes. J. Microbiol. Methods 84 (2011), 81–87.
122. [122] Větrovský, T., Baldrian, P., The variability of the 16S rRNA gene in bacterial genomes and its consequences for bacterial community analyses. PLoS One, 8, 2013, e57923.
123. [123] Nelson, M.C., Morrison, H.G., Benjamino, J., Grim, S.L., Graf, J., Analysis, optimization and verification of Illumina-generated 16S rRNA gene amplicon surveys. PLoS One, 9, 2014, e94249.
124. [124] Westcott, S., Schloss, P., De novo clustering methods outperform reference-based methods for assigning 16S rRNA gene sequences to operational taxonomic units. PeerJ, 3, 2015.
125. [125] O'Toole, P.W., Jeffery, I.B., Gut microbiota and aging. Science 350 (2015), 1214–1215.
126. [126] Biagi, E., et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One, 5, 2010, e10667.
127. [127] van Tongeren, S.P., Slaets, J.P., Harmsen, H.J., Welling, G.W., Fecal microbiota composition and frailty. Appl. Environ. Microbiol. 71 (2005), 6438–6442.
128. [128] Zwielehner, J., et al. Combined PCR-DGGE fingerprinting and quantitative-PCR indicates shifts in fecal population sizes and diversity of Bacteroides, bifidobacteria and Clostridium cluster IV in institutionalized elderly. Exp. Gerontol. 44 (2009), 440–446.
129. [129] Walker, A.W., et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol., 11, 2011, 7.
130. [130] Frank, D.N., et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 13780–13785.
131. [131] Lepage, P., et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 141 (2011), 227–236.
132. [132] Baumgart, M., et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J. 1 (2007), 403–418.
133. [133] Darfeuille-Michaud, A., et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127 (2004), 412–421.
134. [134] Martinez-Medina, M., et al. Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease. Inflamm. Bowel Dis. 15 (2009), 872–882.
135. [135] Martin, H.M., et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 127 (2004), 80–93.
136. [136] Kotlowski, R., Bernstein, C.N., Sepehri, S., Krause, D.O., High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 56 (2007), 669–675.
137. [137] Sasaki, M., et al. Invasive Escherichia coli are a feature of Crohn's disease. Lab. Investig. 87 (2007), 1042–1054.
138. [138] Ohkusa, T., et al. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J. Gastroenterol. Hepatol. 17 (2002), 849–853.
139. [139] Andoh, A., et al. Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis. Inflamm. Bowel Dis. 13 (2007), 955–962.
140. [140] Rajilić-Stojanović, M., Shanahan, F., Guarner, F., de Vos, W.M., Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm. Bowel Dis. 19 (2013), 481–488.
141. [141] Jackson, M.A., et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65 (2016), 749–756.
142. [142] Imhann, F., et al. Proton pump inhibitors affect the gut microbiome. Gut 65 (2016), 740–748.
143. [143] Freedberg, D.E., et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology 149 (2015), 883–885 e889.
144. [144] Montassier, E., et al. 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation. Microb. Ecol. 67 (2014), 690–699.
145. [145] Montassier, E., et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment. Pharmacol. Ther. 42 (2015), 515–528.